The U.S. Department of Health and Human Services said it had approved Eli Lilly’s drug (LLY.N) and Boehringer Ingelheim’s partner, Jardiance, for increased use to reduce the risk of death and hospitalization for all patients with heart failure.
The drug was initially approved by the Food and Drug Administration in 2014 for type 2 diabetics, the use of the drug was increased last year in some adults with heart failure with reduced ejaculation, which occurs when the left ventricular muscle does not pump as well as normal.
“While Jardiance may not be effective in all patients with heart failure, this approval is an important step forward for patients and our understanding of heart failure,” said Norman Stockbridge, director of the FDA’s Department of Cardiology and Renal Medicine.
The expansion on Thursday now increases its market size to reach a very large group of patients, about 6.2 million people, according to information from the Centers for Disease Control and Prevention.
Jardiance is also facing competition from AstraZeneca Plc (AZN.L) drug Farxiga, which is approved for patients with symptomatic heart failure.
Eli Lilly recorded nearly $ 1.5 billion in revenue for Jardiance in 2021, while Farxiga received double that amount for AstraZeneca.
FDA approves Eli Lilly drug to reduce death, risk of hospitalization in all heart patients – SABC News
Source link FDA approves Eli Lilly drug to reduce death, risk of hospitalization in all heart patients – SABC News